Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY307161 crossover study in irritable bowel syndrome
2005-004264-23Phase 2Completed
- Sponsor
- Gastrotech Pharma
- Start
- Oct 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LY307161 in irritable bowel syndrome (IBS) (2 arms), sponsored by Gastrotech Pharma. Primary endpoint: Primary efficacy endpoint. Started Oct 2005; status: completed.
02
Drugs
LY307161
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2005-004264-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004264-23.